Reports
Sale
Small Cell Lung Cancer (Sclc) Market Size, Share, Trends: By Diagnosis: Imaging Tests, Pulmonary Function Test, Lung Tissue Analysis, Others; By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Others; By Route of Administration; By Gender; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Small Cell Lung Cancer (SCLC) Market Outlook:
The small cell lung cancer (SCLC) market size in the 7 major markets is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032. The growth of the market can be attributed to the rising prevalence of small cell lung cancer (SCLC) across these markets.
Small Cell Lung Cancer (SCLC): Introduction
Small cell lung cancer is a rare and lethal lung cancer that grows aggressively. It can affect anyone, but people with a long history of smoking tobacco are most susceptible to SCLC. It can be treated with a high chance of living a healthy life if the disease is detected in the early stages. The only way one can prevent small cell lung cancer is by not smoking.
Small Cell Lung Cancer (SCLC) Market Analysis
The small cell lung cancer (SCLC) market demand is witnessing significant growth due to the increased prevalence of small cell lung cancer (SCLC) among people. The continuous comprehension by the FDA in closing a crucial gap of unmet needs is a major factor expected to be responsible for the growth of the market in the forecast period. For example, the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R). It is therapy that has been developed by a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. Such designations by the FDA are expected to result in innovation among biotech companies dedicated to developing treatments for people suffering from this disease, further bolstering the small cell lung cancer (SCLC) market growth.
Additionally, to find an appropriate treatment for this life-threatening disease, scientists are continuously engaged in research to discover therapeutics that could act effectively in the treatment or prevention of SCLC. Pharmaceutical companies are participating equally in these research activities. For example, Chugai Pharmaceutical Co., Ltd., Japan's pioneering research-based pharmaceutical company with strengths in biotechnology products, recently declared that their phase III BEAT-SC study, evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) and platinum-based chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of progression-free survival (P89uuFS).
Positive results from such studies stand fair chances to play a crucial role in the development of new therapeutics for effective treatment of SCLC provide better patient outcomes, and act as a catalyst in the demand for such treatments, propelling the market growth in the forecast period.
Small Cell Lung Cancer (SCLC) Market Segmentations
Market Breakup by Diagnosis
- Imaging Tests
- Pulmonary Function Test
- Lung Tissue Analysis
- Others
Market Breakup by Treatment
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Others
Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
Market Breakup by Gender
- Male
- Female
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centres
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Small Cell Lung Cancer (SCLC) Market Overview
The market growth is driven by the increasing prevalence of small cell lung cancer (SCLC). The rising number of smokers across the world and especially these 7 regions are the major reasons for the increased prevalence of this condition. Lung cancer is the second most diagnosed cancer worldwide. The market growth is further driven by ongoing research and innovations to bring new treatments for cures and diagnostics to enable early detection of this deadly disease. Such innovations and advancements are expected to exhibit an upward trajectory for the forecast cast and contribute to the small cell lung cancer (SCLC) market share. The increasing initiatives to spread awareness about the lethal nature of tobacco smoking are propelling the market further.
Geographically, the United States is dominating the market due to the increased prevalence of the condition. It is estimated that approximately 14% of people who are diagnosed with lung cancer in the United States have SCLC. The market growth is further driven by the increased adaptation of advanced technologies and the availability of healthcare professionals who are aware of SCLC and its symptoms due to which early detection is possible in patients.
Small Cell Lung Cancer (SCLC) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Lupin
- Merck & Co. Inc.
- CLOVIS Oncology
- Johnson & Johnson Private Limited
- Lilly
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Gender |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Small Cell Lung Cancer (SCLC) Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Small Cell Lung Cancer (SCLC) Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.1 Germany Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.2 France Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.3 Italy Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.4 Spain Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
5.4 Japan Small Cell Lung Cancer (SCLC) Epidemiology Forecast (2017-2032)
6 Small Cell Lung Cancer (SCLC) Market Overview – 7MM
6.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
6.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
7 Small Cell Lung Cancer (SCLC) Market Landscape – 7MM
7.1 Small Cell Lung Cancer (SCLC): Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Small Cell Lung Cancer (SCLC) Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Route of Administration
8 Small Cell Lung Cancer (SCLC) Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Small Cell Lung Cancer (SCLC) Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Small Cell Lung Cancer (SCLC) Market Segmentation – 7MM
11.1 Small Cell Lung Cancer (SCLC) Market by Diagnosis
11.1.1 Market Overview
11.1.2 Imaging Tests
11.1.3 Pulmonary Function Test
11.1.4 Lung Tissue Analysis
11.1.5 Others
11.2 Small Cell Lung Cancer (SCLC) Market by Treatment
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Immunotherapy
11.2.4 Targeted Therapy
11.2.5 Radiation Therapy
11.2.6 Others
11.3 Small Cell Lung Cancer (SCLC) Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.3.4 Others
11.4 Small Cell Lung Cancer (SCLC) Market by Gender
11.4.1 Market Overview
11.4.2 Male
11.4.3 Female
11.5 Small Cell Lung Cancer (SCLC) Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Specialty Centres
11.5.5 Others
11.6 Small Cell Lung Cancer (SCLC) Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Online Pharmacy
11.6.4 Retail Pharmacy
11.7 Small Cell Lung Cancer (SCLC) Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Small Cell Lung Cancer (SCLC) Market
12.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
12.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
12.3 Small Cell Lung Cancer (SCLC) Market by Type
12.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13 EU-4 and United Kingdom Small Cell Lung Cancer (SCLC) Market
13.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
13.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
13.3 Germany Small Cell Lung Cancer (SCLC) Market Overview
13.3.1 Small Cell Lung Cancer (SCLC) Market by Type
13.3.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.4 France Small Cell Lung Cancer (SCLC) Market Overview
13.4.1 Small Cell Lung Cancer (SCLC) Market by Type
13.4.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.5 Italy Small Cell Lung Cancer (SCLC) Market Overview
13.5.1 Small Cell Lung Cancer (SCLC) Market by Type
13.5.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.6 Spain Small Cell Lung Cancer (SCLC) Market Overview
13.6.1 Small Cell Lung Cancer (SCLC) Market by Type
13.6.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
13.7 United Kingdom Small Cell Lung Cancer (SCLC) Market Overview
13.7.1 Small Cell Lung Cancer (SCLC) Market by Type
13.7.2 Small Cell Lung Cancer (SCLC) Market by Treatment Type
14 Japan Small Cell Lung Cancer (SCLC) Market
14.1 Small Cell Lung Cancer (SCLC) Market Historical Value (2017-2023)
14.2 Small Cell Lung Cancer (SCLC) Market Forecast Value (2024-2032)
14.3 Small Cell Lung Cancer (SCLC) Market by Type
14.4 Small Cell Lung Cancer (SCLC) Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Teva Pharmaceutical Industries Ltd.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Sanofi
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 F. Hoffmann-La Roche Ltd.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Mylan N.V.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Pfizer Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 GSK plc
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Novartis AG
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Sun Pharmaceutical Industries Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Aurobindo Pharma
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Lupin
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Merck & Co. Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 CLOVIS Oncology
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Johnson & Johnson Private Limited
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Lilly
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Small Cell Lung Cancer (SCLC) Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to be driven by the increased prevalence of small cell lung cancer (SCLC).
The major factors driving the market demand include increased tobacco smoking, coupled with the increased prevalence of small cell lung cancer (SCLC) across the 7 major markets.
The high investments by the government and increasing initiatives by non-government organizations such as WHO to increase awareness about the disadvantages of tobacco smoking are among the major trends influencing the market growth.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 includes Germany, France, Italy, and Spain.
Different diagnosis available in the market include imaging tests, pulmonary function test, and lung tissue analysis, among others.
The treatments can be divided into chemotherapy, immunotherapy, targeted therapy, and radiation therapy, among others.
The route of administration includes oral and intravenous, among others.
The genders can be divided into male and female.
The end-users in the market include hospitals, homecare, and specialty centres, among others.
The distribution channels in the market include hospital pharmacy, online pharmacy, and retail pharmacy.
Key players involved in the market are Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Mylan N.V., Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Merck & Co. Inc., CLOVIS Oncology, Johnson & Johnson Private Limited, and Lilly.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER